GLP‐2 analogs have been developed as a therapeutic option for patients with SBS‐IF,16 based on the observation that exogenous GLP‐2 enhances fluid and nutrient absorption and reduces malabsorption and diarrhea in both preclinical and clinical SBS settings.17 Here, GCG is linked to macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.